Lilly's Web-Based Research Marketplace

01 Sep 2001

• By Jeff Dvorin

Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with Innocentive LLC, a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing. Innocentive offers a means for pharmaceutical and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.

Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with InnoCentive LLC , a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing from Lilly's e.Lilly Venture Fund. (See "Lilly's E-Venture Fund: Getting In At The Bottom," START-UP, February 2001 [A#2001900027.) InnoCentive offers a web-based means for pharmaceutical, biotech, and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.

The InnoCentive marketplace consists of a web site featuring projects for which the posting companies are seeking scientific assistance. There...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.